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Abstract
Background: Delirium is a state of confusion characterized by an acute and fluctuating decline in cognitive
functioning. Delirium is common and deadly in older adults with dementia, and is often referred to as delirium
superimposed on dementia, or DSD. Interventions that treat DSD are not well-developed because the mechanisms
involved in its etiology are not completely understood. We have developed a theory-based intervention for DSD
that is derived from the literature on cognitive reserve and based on our prior interdisciplinary work on delirium,
recreational activities, and cognitive stimulation in people with dementia. Our preliminary work indicate that use of
simple, cognitively stimulating activities may help resolve delirium by helping to focus inattention, the primary
neuropsychological deficit in delirium. Our primary aim in this trial is to test the efficacy of Recreational Stimulation
for Elders as a Vehicle to resolve DSD (RESERVE- DSD).
Methods/Design: This randomized repeated measures clinical trial will involve participants being recruited and
enrolled at the time of admission to post acute care. We will randomize 256 subjects to intervention (RESERVE-
DSD) or control (usual care). Intervention subjects will receive 30-minute sessions of tailored cognitively stimulating
recreational activities for up to 30 days. We hypothesize that subjects who receive RESERVE-DSD will have:
decreased severity and duration of delirium; greater gains in attention, orientation, memory, abstract thinking, and
executive functioning; and greater gains in physical function compared to subjects with DSD who receive usual
care. We will also evaluate potential moderators of intervention efficacy (lifetime of complex mental activities and
APOE status). Our secondary aim is to describe the costs associated with RESERVE-DSD.
Discussion: Our theory-based intervention, which uses simple, inexpensive recreational activities for delivering
cognitive stimulation, is innovative because, to our knowledge it has not been tested as a treatment for DSD. This
novel intervention for DSD builds on our prior delirium, recreational activity and cognitive stimulation research, and
draws support from cognitive reserve theory.
Trial registration: ClinicalTrials.gov identifier: NCT01267682
Background
Delirium is a state of confusion characterized by an acute
and fluctuating decline in cognitive functioning [1]. The
exact cause of delirium is unknown but typically involves
a vulnerable patient and a noxious insult such as surgery,
infection, or adverse effects from medications [2]. Delir-
ium is common and deadly in older adults with dementia,
and is often referred to as delirium superimposed on
dementia, or DSD. Over 80% of older adults with demen-
tia experience delirium when hospitalized, and studies
report that between 24 and 76% die within one year of
the index episode [3,4]. Delirium often persists long past
the acute phase of an illness and substantially worsens
outcomes in a population already burdened with physical
and cognitive deficits [5,6]. Over two thirds of older
adults admitted to post acute care exhibit delirium on
admission [7]. Unresolved delirium results in an acceler-
ated trajectory of cognitive and physical decline that pro-
longs hospitalization and rehabilitation, and precipitates
premature nursing home placement [4,8-10].
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It is difficult to prevent delirium in persons who
already have reduced cognitive reserve [11]. Efforts to
resolve established delirium are critical to implement
because data indicate that when delirium resolves
slowly, or never at all, less than 50% of pre-illness func-
tioning is realized [12]. These individuals are at high
risk for poor quality of life and institutionalization
because of their resultant functional impairments, their
care becoming too burdensome for family caregivers to
support. Interventions that slow the accelerated down-
ward spiral accompanying DSD have the potential to
make a major public health impact by preserving func-
tion, preventing premature institutionalization and redu-
cing the $152 billion national burden attributed to
delirium [4,13,14].
Unfortunately, interventions that treat DSD are not
well-developed because the mechanisms involved in its
etiology are not completely understood. Historically, the
pathophysiology of delirium has been characterized as a
derangement of the functional metabolism of the brain
[15]. In support of this theory, studies have found
decreased blood flow in varied and diffuse regions of the
brain that normalizes once the delirium resolves [16,17].
On a cellular level there is disruption of cholinergic
transmission [2,18], dopaminergic excess [19], and
elevated markers of inflammation (chemokines and
cytokines) [20].
The primary neuropsychological deficit in delirium is
in the domain of attention; orientation, memory, abstract
thinking and executive function are also affected [21].
These deficits are responsible for the cognitive decline
seen in delirium, and as improvement in these domains
occurs, the fluctuating course typical of delirium resolves
[22,23].
Deficits in physical function, i.e., activities of daily liv-
ing (ADLs) and instrumental activities of daily living
(IADLs) parallel the changes in cognition that accompany
delirium [4,24-26]. Attentional impairments adversely
affect memory performance and may underlie the
impaired ADLs and IADLs seen in delirium [27,28].
Attentional impairments affect loco-motor function and
increase the risk of falls and accidents [28-30]. Indivi-
duals who experience the acute cognitive problems asso-
ciated with delirium are likely to experience problems
with continence, ambulation, dressing, and general way-
finding, among other functional tasks.
Very few studies have examined unique risk factors for
delirium in persons with dementia, although the avail-
able evidence seems to indicate that they are similar to
factors observed in cognitively intact individuals. Voyer
and colleagues found that advanced age, dementia sever-
ity, pain, depression, dehydration, function, behavior,
number of medications, and fever were all predisposing
risk factors for DSD [31]. In a retrospective chart review
of 199 patients with Alzheimer’s Disease (AD), urinary
tract infection (UTI), surgery, stress/bereavement (death
of spouse, change in residence), and severe pain
occurred more frequently in delirious than non-delirious
patients [32]. Using administrative data, our retrospec-
tive review of 7,347 persons with dementia found that
those with DSD were older and treated for higher rates
of cerebrovascular disease, UTI, dehydration, and pneu-
monia [33]. Severity of delirium has been linked to later
stages of dementia [23] and presence of depression [31].
Certain classes of medications are also strong risk fac-
tors for delirium. Persons with dementia take a greater
number of central nervous system (CNS)-active medica-
tions than their cognitively intact counterparts, includ-
ing antipsychotics, anxiolytics, and antidepressants [34].
These drugs are known to increase risk of delirium and
further cognitive deterioration because of their potent
anticholinergic properties [35,36]. Even CNS-active
drugs that are appropriately used can accumulate in
amounts that lead to delirium, sedation, and falls [37].
Also important for this study are data that indicate a
relationship between presence of the apolipoprotein E
(ApoE) *E4 allele and delirium severity and duration.
Though findings have not always been consistent [38],
the weight of the evidence indicates that having at least
one copy of the *E4 allele is associated with an increased
risk of delirium in young and older adults as well as a
more protracted course, independent of demographic
and clinical covariates, or premorbid cognitive impair-
ments [39-42].
Clinical management of established delirium is quite
variable and includes interventions that target risk factors
associated with delirium, but there is no strong empirical
basis for prescribing these interventions [43]. The results of
clinical trials have been quite modest, and, in some cases,
treatments have been ineffective [44-46]. For example,
some data indicate that use of antipsychotics and benzodia-
zepines may actually precipitate delirium and contribute to
further long term cognitive impairment [47,48]. Safe, effica-
cious, and cost-effective non-pharmacological treatments
for delirium are urgently needed.
We have developed a theory-based intervention for
DSD that is derived from the literature on cognitive
reserve and based on our prior interdisciplinary work on
delirium, recreational activities, and cognitive stimulation
in people with dementia. Cognitive reserve is a construct
used to explain the often noted lack of association
between clinical manifestations of brain disease and
actual brain pathology. It includes both passive and active
processes that modify risk for the clinical expression of
disease. Passive reserve, sometimes referred to as “brain
reserve,” is accounted for by brain size and synapse den-
sity [49]. It is hypothesized that individuals with larger
brains and greater synapse density can tolerate more
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extensive pathology before they reach the threshold at
which symptoms become clinically evident. Active
reserve or “cognitive reserve,” refers to the efficiency with
which an individual can use alternate networks or cogni-
tive strategies to cope with the brain pathology. Cognitive
reserve is related to the brains metabolic activity [50] and
is dynamic, active, and can be modified by mental activ-
ity. Brain reserve and cognitive reserve are not mutually
exclusive. Mental activity is a strong signal for the gen-
eration of neurons and synapses [51] and, as discussed
below, evidence for the ability to develop compensatory
mechanisms in late life and early dementia is now
emerging.
Epidemiological studies indicate that individual differ-
ences in cognitive reserve are due to life-time differences
in mental activity; and these activities are considered
markers of cognitive reserve. Individuals with more for-
mal education, who are employed in occupations that are
characterized by greater complexity and who engage in
stimulating leisure activities appear to have greater cogni-
tive reserve than those who participate in fewer mentally
stimulating activities as evidenced by their lower risk for
dementia and later manifestation of clinical symptoms
when a dementia develops [52].
Studies have examined the association of markers of
cognitive reserve and incident delirium. They indicate
that individuals with low levels of educational attainment
and deprivation (living alone) are at greater risk for delir-
ium than individuals with more education or less depri-
vation [8,14,53]. Because education typically occurs in
early life and is not the only source of mental activity
over a lifetime, it is important to consider all forms of
complex activities when assessing cognitive reserve [54].
A lifetime of low mental activity may lead to low cogni-
tive reserve and increase vulnerability to noxious events
that precipitate delirium.
Both delirium and dementia are conditions of reduced
cognitive reserve [2,55,56] and have common risk factors:
a lifetime of low engagement in complex mental activities
[57] and presence of the ApoE *E4 allele [58]. Some
investigators have suggested that because delirium and
dementia share many clinical, metabolic, and cellular
manifestations indicative of reduced cognitive reserve
[55,59], they may be part of the same disorder [2,59]. It is
plausible, then, that interventions that improve cognitive
reserve in dementia may also be effective in delirium.
There is growing evidence that cognitively stimulating
activities improve cognitive functioning in healthy older
individuals and those in mild to moderate stages of
dementia [60-63]. Cognitive stimulation is a specific form
of cognitive-focused intervention, defined as a non-regi-
mented intervention that involves engagement in a range
of activities that promote cognitive processing aimed at
general enhancement of mental and social functioning
[64,65]. In this study we provide cognitive stimulation by
using recreational activities that are tailored to individual
interests and function and that encourage processing in
the multiple cognitive domains affected by delirium.
A number of reviews and meta-analyses have assessed
the effect of cognitive-focused interventions on cognitive
function in older adults with dementia. Unlike in healthy
populations, cognitive training has not received compel-
ling support when used in people with dementia [66,67].
However, the benefits of cognitive stimulation for slow-
ing cognitive decline in Mild Cognitive Impairment
(MCI) and in mild to moderate stages of dementia are
more robust [68-70]. In a trial that used mental status as
primary outcome, effect sizes for cognitive gains asso-
ciated with cognitive stimulation were comparable to
those reported for the acetylcholinesterase inhibitors
[62]. A recent meta-analysis of cognitive-focused inter-
ventions for dementia [71] found that cognitive stimula-
tion had stronger effects for improving cognitive function
than cognitive training. Outcome measures varied from
study to study but included attention, orientation, mem-
ory, abstract thinking and executive functioning. Effects
were greater when delivered in individual as opposed to
group sessions. There is also some evidence that the
effects of cognitive stimulation can be enhanced when
combined with cholinergic drugs [72] but these effects
deteriorate after one year of treatment [73]. Based on the
evidence for the clinical and cost-effectiveness of cogni-
tive stimulation, the National Institute for Health and
Clinical Excellence in the U.K. has included this therapy
in its guidelines for the non-pharmacological treatment
of the cognitive symptoms of dementia [74].
Most of the research on the effects of cognitive stimula-
tion has focused on the progression of dementia. Clinical
observations [75] and our preliminary work [76] indicate
that use of tailored cognitively stimulating recreational
activities may also help resolve DSD. In two clinical trials
[77,78] we demonstrated that we can capture and sustain
attention in nursing home residents with dementia when
we use recreational activities that match individual inter-
ests and abilities. Individual interests are important in the
design of cognitive activities because when people with
dementia are intrinsically motivated to participate in cog-
nitive remediation they obtain greater cognitive and func-
tional benefits [79]. Interesting and enjoyable activities
facilitate cognitive processing in the cognitive domains
affected by delirium: attention, orientation, memory,
abstract thinking, and executive functioning [21]. Cogni-
tive processing helps restore cognitive functioning [64,65],
and in persons with delirium, improved cognitive function
is accompanied by improvement in physical function
[4,24] and resolution of delirium [22,80].
We conducted a pilot study to assess the feasibility of
implementing our intervention in a post acute care
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setting with newly admitted patients who presented with
DSD [76]. We provided cognitive stimulation by using
recreational activities that were tailored to individual
interests and function and that encouraged processing
in the multiple cognitive domains affected by delirium.
All participants had a diagnosis of dementia on admis-
sion and at least 2 symptoms of delirium as assessed by
the Confusion Assessment Method [105]. We rando-
mized 16 subjects to treatment with cognitively stimu-
lating activities (N = 11) or usual care control (N = 5)
and followed participants for 30 days. Blinded research
assistants conducted daily assessments of delirium, delir-
ium severity and functional status. Participants in the
treatment group received activities for 30 minutes each
day. Analyses indicated that the control group had a sig-
nificantly greater decrease in physical function and men-
tal status over time compared to intervention. Severity
of delirium approached significance and improvement
over time favored intervention. Although not statistically
significant, there was a difference in mean (7.0 vs. 3.27)
and median (7.0 vs. 3.0) days with delirium: the control
group having more days of delirium. We were encour-
aged by these results and are ready to conduct a rando-
mized clinical trial of treatment efficacy.
This paper describes the study protocol for our rando-
mized clinical trial (RCT), referred to as Recreational
Stimulation for Elders as a Vehicle to resolve DSD
(RESERVE- DSD) in which we test these cognitively sti-
mulating activities. The aims of the trial are: Aim 1) to
demonstrate the efficacy of the RESERVE-DSD interven-
tion for resolving delirium; Aim 2) to evaluate potential
moderators (markers of cognitive reserve) of RESERVE-
DSD efficacy; and secondary Aim 3) to describe the
costs associated with implementing the intervention.
Our hypothesized model of intervention effect is dia-
gramed in Figure 1.
Methods/Design
This randomized repeated measures clinical trial will
involve participants being recruited and enrolled at the
time of admission to post acute care, and then randomly
assigned to one of two conditions: RESERVE-DSD (inter-
vention) or usual care (control) (See Figure 2: Trial flow
diagram.)The study protocol was approved by the Penn
State Institutional Review Board (IRB# 33443). Partici-
pants in the intervention group will receive nursing care
that is routinely delivered for their medical/surgical con-
dition including participation in their prescribed thera-
pies plus RESERVE-DSD. At the present time there is no
standard care for DSD [43,81]. Participants in the usual
care group will receive nursing care that is routinely
delivered for their medical/surgical condition including
participation in their prescribed therapies.
The two-group experimental design we propose may
not completely control for the many variables that can
affect DSD. We will control as much as possible for fac-
tors we believe are most likely to impact our findings
through strict enrollment criteria, and by considering
several potential covariates in our analyses: dementia
stage, co-morbidities, age, use of CNS-active drugs, pain,
infection, dehydration, APOE status, and lifetime com-
plex mental activity including years of formal education,
occupation, and past leisure activity.
Setting and Participants
The study will be conducted in five Northeast, Central,
and South-central Pennsylvania nursing homes that pro-
vide rehabilitation services (post acute/skilled nursing
care). Sites were selected to ensure a large population for
recruitment and to increase the diversity of the sample.
To improve the potential for translation into practice and
to increase the generalizability of our findings we have
selected a mix of for-profit, nonprofit, county-owned,
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rural and urban, and large, medium, and small commu-
nity-based settings.
Participants are individuals with DSD who are admitted
to post-acute care following hospitalization. These indivi-
duals will meet the following inclusion criteria: age 65
years or older; English speaking; community residing
prior to hospitalization; diagnosis of mild to moderate
stage of dementia as confirmed by medical chart review
and/or a score of 0.5 to 2.0 on the Clinical Dementia Rat-
ing Scale [82]and a score of 3 or greater on the Modified
Blessed Dementia Rating Scale [83]; and at least two fea-
tures of delirium as assessed by the Confusion Assess-
ment Method. A consensus panel of three members with
expertise in geriatric medicine, neuropsychology, and
delirium will adjudicate all dementia and delirium diag-
noses. Exclusion criteria include: severe hearing, speech
InformedConsentObtained:BaselineMeasures(ChartReview,APOE&LEQ)ȋαʹͷ͸Ȍ
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Figure 2 Reserve-DSD Trial Flow Diagram.
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or vision impairments; medical diagnoses of acute major
depression, acute psychiatric condition, acute stroke, Par-
kinson’s disease, Huntington’s disease, normal pressure
hydrocephalus, seizure disorder, subdural hematoma,
head trauma, or known structural brain abnormalities; or
a life expectancy of less than 6 months. Participants who
satisfy all enrollment criteria will be invited to participate
in the study.
Consent Process
Participants in this study will be frail older adults who lack
decisional capacity due to their delirium superimposed on
dementia. Participants and their legally authorized repre-
sentative (LAR) will be approached for screening and con-
sent (for those found eligible) at the point of admission to
post-acute care. The LAR will sign for the participant and
a copy of the consent will be given to them. We ask the
participant for assent on a daily basis prior to assessment
and intervention.
Randomization and Control of Cross-Contamination
Randomization will be concealed until after the initial
screen and consent are obtained and an ID number is
assigned to the participant. The statistician will generate
the randomization sequence using a random number
generator. Randomization will be conducted in blocks by
nursing home site and time to ensure equal assignment
across the two groups at the completion of the study and
approximately equal assignments throughout the study
to control for unknown temporal effects. The statistician
will be blinded to treatment coding.
Our team discussed several randomization procedures
and we have elected to randomize by participant rather
than by site, even though the latter approach is an excel-
lent method for controlling cross-contamination of con-
ditions. There are several reasons for our decision. First,
nursing homes are unstable environments [84] and there
is evidence indicating that nursing home quality indica-
tors are unstable from one six-month period to the next
[85]. Changes in quality indicators may reflect change in
quality of care and/or resident profile. Either could
potentially impact our outcomes because of their likely
effect on usual care. Second, we are confident that we
can control treatment contamination within sites, and for
the same sample size, randomization by participant will
provide greater power than randomization by nursing
home.
We control for cross-contamination by conducting all
interventions using our trained research assistants (RAs)
(not nursing home staff) in an area specifically set aside
for these sessions. Nursing homes have provided us with
this research space in the past and staff has always
respected our procedures for control of cross-contami-
nation. Only the resident scheduled for a particular
session will be allowed access to the area for that time
period.
Intervention
Participants in the intervention group will receive nur-
sing care that is routinely delivered for their medical/sur-
gical condition including participation in their prescribed
therapies plus RESERVE-DSD. This intervention consists
of increasingly challenging recreational activities that are
cognitively stimulating and tailored to each participant’s
interests and functional abilities. The recreational activ-
ities target cognitive functions affected by delirium:
attention, orientation, memory, abstract thinking, and
executive functioning. Participants will receive up to 30
minutes of their respective recreational activities once a
day between the hours of 1 pm and 5 pm for up to 30
consecutive days beginning within 24 hours of admission
to post acute care.
The cognitively stimulating recreational activities to be
studied are from previously designed, well-established
programs of therapeutic activities from Drs. Kolanowski
and Clare’s research on the behavioral and cognitive
symptoms of dementia, respectively. We have con-
structed a large base of cognitively stimulating recrea-
tional activities, many taken from the growing literature
on brain fitness [75,86-90]. The activities, such as word
search, finish the phrase, and name that tune, offer sti-
mulation in multiple cognitive domains, combined in
novel ways, as opposed to stimulation in a single cogni-
tive domain like memory training.The investigators have
classified the base of recreational activities by most pro-
minent domain stimulated, however, in actuality activities
stimulate several cognitive domains simultaneously. For
example, the game of “Name that Tune” requires proces-
sing in the areas of both attention and memory. Multi-
domain cognitive activities demonstrate more robust
results than single domain training [91]. The activities
are implemented using inexpensive items and are readily
available to most nursing homes. Because they require no
special expertise to implement, they are well-suited to
the resource-stressed nursing home environment.
Assessment and Prescription
The selection of activities for each participant will be
determined by Drs. Kolanowski and Clare. Each partici-
pant’s baseline data, including dementia stage, physical
function, and activity interests are reviewed. Based on
this assessment, three recreational activities tailored to
the participant’s functional abilities and designed around
themes of their interests will be selected by level of diffi-
culty (easy, moderate, and hard) in each cognitive
domain. For example, a participant who has arthritic pro-
blems with their hands, a mild stage of dementia, and a
history of interest in gardening might be prescribed:
identify the sound of a lawn mower (attention); discuss
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whether the current calendar month is good for planting
(orientation); memory tray with three or more garden
tools (memory); describe steps to planting a garden
(abstract thinking); and having the participant plant
flower seeds using adapted hand tools (executive func-
tioning). Using the domain of attention as an example,
increasing the level of difficulty might proceed in this
fashion: lawn mower sound identification (easy); circle
the garden tools in a picture (moderate); item search of
vegetables embedded in a “busy” picture (difficult). We
provide variety from day to day to encourage cognitive
processing and to prevent a practice effect.
Procedure for Implementation
To encourage initial engagement in the activity, the
research assistant (RA) will use the System of Least
Restrictive Prompts [92] beginning with verbal cueing,
followed by verbal cueing and demonstration of the
activity. Participants are then encouraged to read out
loud, point out facts, work puzzles, ask questions,
answer questions, or make choices. RAs will use princi-
ples for implementing cognitive activities outlined by
Green & Bavelier [93]: active engagement, incremental
increases in task difficulty; verbal encouragement and
motivation throughout the session; feedback and praise;
and variability in tasks. These approaches maximize cog-
nitive processing and restoration.
Scheduling and Duration of Intervention
Participants will receive the intervention for 30 minutes
each day for up to 30 consecutive days between the
hours of 1 pm and 5 pm. This dosage is based on a con-
sensus report of activity effectiveness compiled by expert
recreational therapists from the American Therapeutic
Recreation Association and the National Recreation
Society [94], standard recreational therapy practice in the
nursing home, and studies that have demonstrated the
efficacy of daily, 30-minute recreational therapy for beha-
vioral symptoms and functional impairment in persons
with dementia [95-97].
Treatment Fidelity
We use several methods to monitor and enhance the
reliability of our intervention [98,99]. Intervention RAs
are trained in a two-day program that we have developed,
standardized, and used for many years to prepare RAs for
implementing recreational activities with people who
have dementia. These RAs need no special educational
background because the activities we use are simple,
non-technical games, and exercises. RAs will practice in
simulated situations until they achieve 100% agreement
on all critical elements of activity intervention before
going into the field. The project director (PD) will moni-
tor delivery of the treatment by observing each RA con-
duct interventions on 10% of sessions in the field
(randomly selected). Retraining will be initiated if treat-
ment fidelity is not obtained, as assessed by any “no”
answer on the treatment fidelity checklist. Additionally,
RAs will complete a treatment fidelity check for any
intervention session that was not delivered according to
protocol. We will monitor receipt and enactment of
treatment using measures for participant adherence to
the protocol: intervention dose (time on task and level of
participation) and duration (number of treatment days
received). Our methods and measures will help us to
monitor and ensure the reliability of our intervention, its
delivery, receipt and enactment.
Description of Usual Care (Control)
At the present time there is no standard care for DSD
[43,81]. Participants in the usual care group will receive
nursing care that is routinely delivered for their medical/
surgical condition including participation in their pre-
scribed therapies. To describe what constitutes usual care
(control) we will conduct medical chart reviews on all par-
ticipants (intervention and control) and extract data on
the following: attendance at prescribed therapies and activ-
ity programs; CNS-active drug use (regular and prn); and
nursing interventions recorded for behaviors nurses use to
describe delirium [100]: confusion, disorientation, altered
mental status, agitation, inappropriate behavior, mental
status change, inattention, hallucination, and lethargy.
Because the nursing home environment is unstable
[84,85], we will also record data every six months on staff-
ing ratios at each site, as published on the Pennsylvania
Department of Health website, and assess staff knowledge
of delirium using our previously developed case vignettes
[101]. We will ask all consenting staff (RN, LPN, and
CNAs) to complete the vignettes at baseline and then
every six months during data collection to capture any
change in overall level of delirium knowledge per site that
might occur due to historical factors or staff turnover in
the nursing home. We will use these data to quantify
usual care and to monitor any qualitative differences
between sites.
Measures
Baseline Measures
Following consent, the PD will collect baseline data on all
participants. From the medical chart the PD will extract
demographic data, all medical diagnoses, and all medica-
tions and therapies prescribed using an investigator-
developed Baseline Medical Chart Review Form. For all
chart reviews we will incorporate methods that help
improve the precision of data abstraction [102,103].
To determine ApoE status, the PD will obtain buccal
swabs from all participants using a procedure established
by the Huck Institutes of Life Sciences Genome Core
Facility (GCF) at Penn State. ApoE status will be deter-
mined by extracting DNA from the buccal swabs using a
protocol optimized by the Institute of Psychiatry in
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London [104]. To identify the six ApoE genotypes com-
prising the ApoE *E2, *E3 and *E4 alleles, two single
nucleotide polymorphisms (SNPs) will be assayed using
the TaqMan Allele Discrimination method. Based on the
distribution in the AD population, we expect that
approximately 40-45% of our sample will carry at least
one *E4 allele [105].
Assessment of participants’ lifetime of complex mental
activities, a measure of cognitive reserve, will be obtained
by interviewing a knowledgeable informant using the
Lifetime of Experiences Questionnaire (LEQ) [54] a reli-
able and valid instrument for assessing educational, occu-
pational, and leisure lifestyle activities that are protective
against cognitive decline. The LEQ consists of 42 items
constructed around two dimensions: three life stages
(young, mid, and late adulthood) and specific vs. non-
specific mental activity in each stage. Scores are calcu-
lated for each stage and then summed for a total LEQ
score. Higher scores indicate higher lifetime mental activ-
ity. The LEQ has an overall internal consistency of .66,
test-retest reliability of .98 and is discriminate between
older adults with high and low mental activity levels.
Healthy older adults with higher LEQ scores have shown
less cognitive decline over 18 months than those with
low scores, independent of covariates [54].
Activity interests will be assessed for participants ran-
domized to RESERVE-DSD by interviewing the respon-
sible party using an adapted version of the Farrington
Leisure History Checklist [88]. This checklist contains
150 recreational activities categorized by games, social,
outdoor and cultural activities. These data will be used
to adapt cognitively stimulating recreational activities
around themes that match participants’ interests.
Measures of Primary Outcomes
Our primary outcomes are: 1) delirium (duration and
severity), 2) cognitive function, and 3) physical function.
Because delirium status fluctuates, and because cognitive
and physical function also fluctuates with delirium status,
we will take daily measures of these outcomes to capture
the variability typical of DSD. Blinded RAs will collect
outcome data. We will have two separate groups of RAs:
one to implement the intervention and the other to con-
duct daily assessments. Daily assessments will be com-
pleted during the morning hours (9 am to 11 am) and
the intervention will be implemented during the after-
noon hours (1 pm to 5 pm) to ensure that there is no
contact between the two groups of RAs
Delirium will be measured by a structured interview
consisting of questions from the Montreal Cognitive
Assessment (MoCA) [106] observation and the Confusion
Assessment Method (CAM) [107]. The MoCA is a brief
cognitive screening tool that demonstrates excellent sen-
sitivity (90% and 100%) in MCI and early AD respec-
tively, and specificity (87%). Content validity was
established by the high correlation (.87) between the
MoCA and MMSE. MoCA items on orientation, mem-
ory and language are used in the assessment of delirium.
The CAM is a standardized screening algorithm allow-
ing persons without formal training to quickly and accu-
rately identify delirium. The CAM has four features:
1) acute onset and fluctuating course, 2) inattention,
and either 3) disorganized thinking, or 4) altered level of
consciousness [107]. A participant is scored as having
subsyndromal delirium if they exhibit any two features
and full delirium if they exhibit features one and two
and either three or four [108]. The CAM was validated
against geriatric psychiatrists’ ratings using DSM-III-R
criteria and has been shown to have a sensitivity
between 94% and 100% and a specificity between 90%
and 95% [107,109]. The CAM has also been validated in
persons with dementia. Studies have shown the utility of
a daily CAM in identifying delirium and its waxing and
waning states [110]. Delirium will be recorded daily by
RAs as present or absent; full or subsyndromal; hyperac-
tive, hypoactive or mixed [111]. Delirium Duration will
be calculated as total number of days with full or sub-
syndromal delirium. Delirium severity will be measured
daily using the Delirium Rating Scale (DRS) [112],a 16-
item clinician-rated scale validated in both delirium and
dementia groups, and having good sensitivity, specificity
and high interrater reliability (ICC 0.97). Scores range
from 0 to 39; higher scores indicate greater severity.
Cognitive Function will be measured with several instru-
ments that capture the cognitive domains affected by
delirium: attention, orientation, memory, abstract thinking,
and executive function. These domains are also affected in
dementia, but previous studies have shown that as they
improve, DSD resolves [22,80]. Digit Span (forward and
backward) is a subtest of the Wechsler Adult Intelligence
Scale (WAIS) and a classic measure of attention [113].
Participants are given increasingly longer sequences of
digits to repeat initially forwards then backwards and
receive a point for each correct sequence. The assessment
ends when the participant misses two sequences in a row.
The maximum possible score is 16 (forward) and 14
(backward). Higher scores indicate better attention and
working memory. Median reliabilities reach .97 and .96 for
forward and backward spans respectively [114,115]. MoCA
items on orientation and memory will be used to measure
those domains. The Similarities test of the verbal Wechsler
Adult Intelligence Scales (WAIS) will be used to measure
abstract thinking. The Similarities test has 18 items requir-
ing the participant to describe how two given things are
alike (ex., a hamburger and pizza). The Similarities test
measures concrete, functional, and abstract thinking. The
WAIS was revised to cover normative data for individuals
16-89 years old with strong reliability and validity
reported. Reliability coefficients for the WAIS and
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Similarities test range from .93-.70 and test-retest reliabil-
ity has been consistently in the .80s [116]. The CLOX
[117] will be used to measure executive function. It is an
easy to administer clock drawing task that elicits impair-
ment in executive function and discriminates it from non-
executive constructional failure. The CLOX has two parts:
CLOX 1, a free drawing of a specified time, and CLOX 2, a
simple copying task. Both steps are rated on 14 items with
scores ranging from 0 to 15, higher scores indicate better
executive function. The CLOX has an internal consistency
of .82, interrater reliability of .94 (CLOX 1) and .93 (CLOX
2) and correlates strongly with measures of cognitive func-
tion in healthy and cognitively impaired older adults
(MMSE and EXIT25).
Physical Function will be measured using the Barthel
Index (BI) [118,119], a commonly used ordinal scale for
assessing activities of daily living in patients receiving
inpatient rehabilitation. The BI has ten items (seven for
self-care and three for mobility) that are scored in steps
of five points with a total score range of zero (totally
dependent) to 100 (fully independent). The BI is a reli-
able indicator of functional ability in older adults when
administered by face-to-face interview (ICC 0.89) and on
testing by different observers (ICC 0.95-0.97) [118,120].
Measures of Moderators of RESERVE-DSD
At baseline we will collect data on potential moderators
of the intervention: we will use the Lifetime of Experi-
ences Questionnaire (LEQ) [54] to obtain a measure of
baseline cognitive reserve; and we will obtain buccal
swabs for DNA extraction to identify the six ApoE geno-
types comprising the ApoE *E2, *E3 and *E4 alleles [104].
These measures are described under baseline measures.
Measures of Variables Affecting Vulnerability
Dementia stage, age, comorbidity, pain, infection, dehydra-
tion and CNS-active drugs. Measures of these variables
will be obtained during screening (dementia stage: Clinical
Dementia Rating Scale), following consent at baseline (age,
comorbidities: baseline chart review), daily (presence of
pain), and weekly (infection, dehydration and CNS-active
drugs: weekly chart review). We will use the Charlson Co-
morbidity Index, a weighted index that takes into account
the number and seriousness of co-morbid diseases, to cal-
culate a co-morbidity score for each participant [121].
Pain will be measured daily using the Pain Assessment in
Advanced Dementia (PAINAD) scale which is an observa-
tional scale of five items (breathing, vocalization, facial
expression, body language, and consolability). We use an
observational rather than a verbal scale for greater reliabil-
ity on days when participants experience greater severity
of delirium. PAINAD is scored from 0-10 and has an inter-
nal consistency reliability of 0.50-0.65 and interrater relia-
bility of 0.82-0.97 [122,123]. Infection and dehydration will
be identified as present or absent (yes/no) during the
weekly chart review. The trained RA will review new
medical orders, lab values and nurses notes for indicators
of infection and dehydration. CNS-active drugs can further
cognitive deterioration because of their potent anticholi-
nergic properties [35,36]. We identify CNS-active drugs
administered through a weekly chart review using the
American Hospital Formulary Service drug classification
[36]. We then calculate the anticholinergic burden asso-
ciated with these drugs using the Anticholinergic Cognitive
Burden (ACB) Scale [124,125]. The ACB is an expert
based practical index that classifies the severity of a drug’s
anticholinergic activity on cognition using a scale of 1
(mild), 2 (moderate) and 3 (severe). Total ACB is calcu-
lated by summing the ACB scores of all regularly and prn
scheduled drugs administered to the participant for that
week. We will weigh the ACB score for each drug by days
administered during that week before summing for the
total ACB score.
Measures of Dosage and Satisfaction with Intervention
Intervention efficacy is often related to dose. During each
intervention session, dosage will be obtained by the RA
using a stop watch to time the minutes and seconds that
the participant engaged in activities (time on task: 0 to 30
minutes). The RA also rates the Level of Participation
using a scale developed by Kovatch and Magliocco for
measuring extent of participation in recreational activities
(an indicator of cognitive processing) [126]. Scores range
from 0 to 3 with descriptors for each numerical rating
(dozing, null, passive, active), higher scores indicate
greater participation. In our work we achieved interrater
reliabilities (ICC) of .99 for time on task and .83 for Level
of Participation. Total dosage received will be calculated
by weighing each daily time on task score by level of par-
ticipation score and then summing across intervention
days. We will use these data to conduct analyses of the
effect of dosage on primary outcomes of the intervention.
Activities attempted per cognitive domain are recorded
daily.
Because we wish to improve the potential for translating
our intervention into practice, we will use investigator-
developed Satisfaction Surveys to assess staff, family, and
participant reports of satisfaction with RESERVE-DSD.
These brief surveys are collected at the completion of the
30-day intervention period or at discharge, whichever
comes first. We will use these data to refine our interven-
tion for a future effectiveness study.
Other Measures
Length of stay, discharge disposition, rehospitalization,
institutionalization, and death will be obtained by using
an investigator-developed Weekly Chart Review. To
further help describe usual care we will assess staff
knowledge of delirium using our case vignettes [101] at
baseline and every 6 months to capture any change in
overall level of delirium knowledge per site that might
occur due to historical factors or staff turnover in the
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nursing home. The case vignettes include five standar-
dized cases that depict different hospitalized patients
experiencing dementia, hypoactive delirium, hyperactive
delirium, hyperactive DSD and hypoactive DSD. The case
vignettes were intended to assess staff ability to identify
different subtypes of delirium and delirium superimposed
on dementia in a standardized format, as well as to gather
qualitative data from the staff. All case vignettes were
completed by 4 expert panelists. Their overall agreement
on the cases was 84%, with a kappa of 0.69. For identifi-
cation of delirium motoric subtype expert agreement was
100% with a kappa of 1.0 [101]. We will also record staff-
ing ratios at each site every six months by accessing the
Pennsylvania Department of Health website where these
data are published.
We will conduct a three-month follow-up to track the
trajectory of delirium resolution. We are not powered to
conduct analyses with the data from this three-month
follow-up. These data will be used to help calculate the
sample size needed for a future multisite study that will
focus on long term outcomes of RESERVE-DSD effec-
tiveness. The three month point approximates a Medi-
care benefit period for skilled care (100 days), so we
should be able to capture data reflecting variability on
these longer term outcomes as participants will likely be
either discharged to home, assisted living or transferred
to a long-term care facility for continuing care at that
point. We will contact the responsible party by phone
and obtain information on the participant’s length of stay
in post acute care (if we do not have this information at
the 30 day point), any additional re-hospitalizations, insti-
tutionalization and death. We will interview the responsi-
ble party using the CAM and telephone MMSE to assess
the participant’s current delirium status. In a study of 41
older adults discharged to home following hip surgery,
the telephone method of assessing delirium showed a
sensitivity of 1.00 and specificity of 0.94 [127].
Statistical Analysis
Prior to conducting any statistical analyses, the distribu-
tions of all sample data will be examined. Extreme values
will be compared with the original data collection forms
in order to identify and correct data entry errors. Follow-
ing this data validation step, sample distributions will be
evaluated to determine if they meet the assumptions
necessary for use of normal distribution-based statistical
methods. If the data are not normally distributed, suitable
transformations will be sought to normalize them. Possi-
ble transformations include log, square root, and rank
transformations. If the data are not sufficiently normal-
ized by transformation, the analysis may proceed using
permutation testing to determine significance levels.
Categorical variables will be evaluated using models
based on the binomial or multinomial distributions. The
design of this study is a two-group randomized design
within blocks defined by individual nursing homes.
Randomization will be conducted at the participant level,
so that intervention groups are crossed with nursing
homes, rather than nested within them. Repeated mea-
surements will be made within individual participants for
up to 30 days. The statistical methods must appropriately
account for within-participant correlation among these
repeated measurements.
The primary statistical model will be mixed-model ana-
lysis of variance (ANOVA). A term representing individual
participants will be included as a random effect in the
model in order to account for correlated multiple mea-
surements for each participant. Treatment and covariates
will be included as fixed effects. The primary outcome
variables are delirium severity and duration, and cognitive
and physical functioning.
The primary analyses will be based on intent to treat.
Thus, participants will be included in the analyses regard-
less of their level of participation in the treatments or of
their loss to follow-up. Participants who have missing
data for some time points will not be excluded from ana-
lyses. The methodology incorporates all available mea-
surements for each participant into the analysis. Missing
values for some observation times will not cause the par-
ticipant’s entire record to be excluded from the analyses,
as may occur in usual repeated measures models.
Potential confounders will be included as covariates in
the analysis. If a variable substantially alters either the
significance level of a group comparison or a measure of
association, that variable will remain in the model in
order to control for its confounding effect. Variables that
will be evaluated as covariates include those that increase
delirium severity and duration, acetylcholinesterase inhi-
bitors, and potential moderators of the association
between treatment and outcome.
In order to evaluate differences in change across the
study period between the intervention groups, time, and
group by time interaction terms will be included in the
model. A significant group by time interaction will be of
interest, as it would reflect differences in rates of change
between the groups. A significant interaction term could
yield a non-significant test for the main effect of group,
but could reflect an important effect of the intervention.
If the test for interaction is significant, the nature of the
interaction effect will be evaluated using means plots and
post-hoc contrasts.
Hypothesized moderator variables will be evaluated
using LISREL and SAS software. Structural models will be
specified based on the path diagram presented previously.
The path diagram will be used to define the hypothesized
structure of the relationships among the variables. Multile-
vel structural equations modeling (SEM) will be used to
evaluate the hypothesized structure, including testing the
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hypothesized moderator status of the cognitive reserve
variables. Tests for moderation are based on regression
relationships among the specified variables. These rela-
tionships are specified in the SEM model and may be
tested based on statistical significance of parameters for
direct and indirect effects in the hypothesized model.
These relationships can also be tested using sets of mixed-
model regression analyses [128-130]. This approach, based
on the “Baron and Kenny steps” [128] will be implemented
as supplemental analyses using SAS software. Using the
regression approach, moderating effects are evaluated as
the interaction effect of X and M. Least-squares means
with 95% confidence intervals will be used to summarize
moderated effects.
One goal of the study is to describe the costs associated
with the RESERVE-DSD intervention and developing
methods for documenting these costs. This information is
important for evaluating the public health impact of the
intervention. Because this is a new intervention with little
data describing its cost, activity-based costing methods
will be used. Determining the cost of the intervention will
involve several steps. First, resources used to deliver the
intervention will be determined. These resources will
include personnel, supplies and other expenses. Next, the
amounts used of these resources will be documented. In
the case of personnel time, the amount of time spent on
activities related to the intervention will be determined
using activity diaries for assessment and prescription time,
and direct observation by study personnel using the time
on task measure for the intervention. Finally, the amounts
used of each resource will be multiplied by the unit cost of
each resource to determine the cost associated with the
resource. For personnel costs, the time spent by each pro-
vider on activities related to the intervention will be multi-
plied by the hourly compensation, including benefits,
associated with the provider. Finally, costs will be summed
across all components of the intervention and divided by
the number of patients treated to determine the average
cost per patient of delivering the RESERVE-DSD interven-
tion. Because different nursing homes might use different
types of personnel for some intervention activities, sensi-
tivity analyses will be used to determine the effect of using
different types of personnel on the cost of the intervention.
Hence, in addition to the actual average cost of providing
the intervention, projected costs based on different types
of appropriate personnel providing the intervention will
also be constructed. These data will inform a future cost-
effectiveness study.
Discussion
Our work and that of others has shown that delirium is
a common, deadly, persistent, and costly problem in
people with dementia. There is strong support for tar-
geting patients with DSD at admission to post acute
care as a high risk group for poor health outcomes. In
these settings persistent cognitive decline is a predictor
of functional dependency [25]. When delirium is unre-
solved, rehabilitation is hampered because the associated
cognitive problems (i.e., inattention, disorientation etc)
interfere with patients’ ability to fully engage in restora-
tive therapies. Our goal is to facilitate maximal rehabili-
tation benefits so these individuals can return to their
homes.
The data also show a compelling need to develop non-
pharmacological interventions that resolve DSD in a
population that is vulnerable to the effects of current
pharmacological treatments. Our study is significant
because it will address this critically important clinical
problem and its lack of effective treatment. We will test
the efficacy of cognitive stimulation (RESERVE-DSD),
an intervention that has helped improve cognitive func-
tioning in people with dementia, and holds promise for
successfully managing those with DSD. This study will
also examine important moderators of intervention
effectiveness to help us determine those most responsive
to treatment. Armed with this knowledge we will be
able to tailor RESERVE-DSD with more precision and
for greater effect.
RESERVE-DSD has the potential to reduce poor
health outcomes that are major sources of today’s spiral-
ing health care costs. The societal implications of help-
ing older individuals with dementia regain adequate
function after hospitalization in order to return to their
homes are enormous in terms of aging in place, quality
of life, cost, and caregiver burden. Our theory-based
intervention, which uses simple, inexpensive recreational
activities for delivering cognitive stimulation, is innova-
tive because, to our knowledge it has not been tested as
a treatment for DSD. This novel intervention for DSD
builds on our prior delirium, recreational activity and
cognitive stimulation research, and draws support from
cognitive reserve theory, one of the most exciting per-
spectives in cognitive research today.
Abbreviations Used
DSD: Delirium Superimposed on Dementia; Reserve For DSD: Recreational
Stimulation for Elders as a Vehicle to resolve DSD;
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